dear
editor
first
case
new
coronaviru
report
decemb
group
patient
admit
hospit
initi
diagnosi
pneumonia
unknown
etiolog
initi
outbreak
new
coronaviru
coronaviru
diseas
formerli
central
provinc
hubei
republ
china
later
spread
mani
countri
infect
appear
caus
wide
rang
symptom
encompass
asymptomat
infect
mild
infect
upper
respiratori
tract
sever
viral
pneumonia
respiratori
failur
multipl
organ
failur
death
studi
shown
detail
clinic
featur
patient
laboratori
confirm
patient
china
almost
critic
ill
almost
critic
patient
die
overal
rate
fatal
case
higher
observ
season
influenza
death
involv
older
adult
mani
underli
chronic
diseas
children
less
like
develop
sever
infect
despit
avail
data
far
anecdot
data
itali
show
huge
number
death
elderli
pave
way
drastic
control
measur
worldwid
compassion
use
drug
sever
case
chloroquin
cq
unequivoc
demonstr
vitro
inhibit
effect
infect
precoci
public
benefici
effect
patient
studi
conduct
marseil
franc
show
viral
load
reduct
patient
sinc
specif
antivir
therapi
coronaviru
infect
date
announc
partial
fragil
data
led
precipit
polit
manifest
major
govern
leader
contribut
uncoordin
recommend
drug
sever
patient
consid
cq
low
cost
good
safeti
profil
vitro
activ
viral
diseas
preexist
suppli
chain
potenti
public
privat
augment
product
knowledg
specif
manag
side
effect
accumul
decad
use
antimalari
use
expect
clinic
assay
promptli
design
multicentr
evalu
actual
potenti
drug
treat
sever
case
cq
sulfat
phosphat
salt
hydroxychloroquin
hcq
use
antimalari
drug
decad
hcq
deriv
cq
first
synthes
introduct
nhydroxyethyl
side
chain
place
qc
ndiethyl
group
prove
less
toxic
prolong
use
therefor
recommend
treatment
autoimmun
diseas
system
lupu
erythematosu
rheumatoid
arthriti
patient
expos
drug
month
eventu
year
sever
studi
current
carri
cq
hcq
howev
research
publish
preliminari
result
studi
cancel
mainli
due
reduct
case
china
prepar
manuscript
march
trial
regist
clinicaltrialsgov
platform
studi
carri
brazil
use
cq
hcq
azithromycinaddit
trial
regist
chines
clinic
trial
registri
state
withdrawn
http
wwwchictrorgcnindexaspx
larg
number
studi
conduct
drug
show
scientif
commun
make
great
effort
clarifi
role
drug
reduc
mortal
associ
effort
probabl
suffici
well
coordin
yet
differ
treatment
length
treatment
dose
regim
report
howev
urgent
need
adapt
clinic
trial
design
order
properli
rapidli
respond
differ
question
observ
pandem
adapt
clinic
trial
contribut
greatli
advanc
patient
care
byincreas
effici
flexibl
random
clinic
trial
reduc
cost
increas
likelihood
find
true
benefit
intervent
studi
sever
defici
tradit
random
clinic
trial
rct
observ
includ
larger
sampl
size
lengthi
durat
lack
power
evalu
global
efficaci
import
subgroup
cost
limit
medic
innov
especi
emerg
scenario
final
need
urgent
answer
limit
current
scenario
also
use
prepar
futur
pandem
consid
case
avail
studi
feasibl
meantim
happen
china
mani
trial
interrupt
case
appear
time
studi
readi
get
start
current
sever
obstacl
still
need
discuss
address
tabl
use
placebo
group
sever
patient
effect
show
treatment
efficaci
lack
instantan
fund
need
time
protocol
approv
ethic
board
worldwid
use
multicentr
studi
rather
singlecent
studi
complianc
good
clinic
practic
order
promptli
find
answer
pandem
still
ongo
use
placebo
patient
critic
disaeas
would
best
way
prove
efficaci
differ
intervent
test
could
consid
uneth
mani
sinc
compassion
clinic
conduct
treat
case
arund
globe
moment
believ
placebocontrol
trial
carri
nonsever
cohort
